145 related articles for article (PubMed ID: 38311182)
1. LipidSIM: Inferring mechanistic lipid biosynthesis perturbations from lipidomics with a flexible, low-parameter, Markov modeling framework.
Liang C; Murray S; Li Y; Lee R; Low A; Sasaki S; Chiang AWT; Lin WJ; Mathews J; Barnes W; Lewis NE
Metab Eng; 2024 Mar; 82():110-122. PubMed ID: 38311182
[TBL] [Abstract][Full Text] [Related]
2. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
[TBL] [Abstract][Full Text] [Related]
3. Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH.
Zanieri F; Levi A; Montefusco D; Longato L; De Chiara F; Frenguelli L; Omenetti S; Andreola F; Luong TV; Massey V; Caballeria J; Fondevila C; Shanmugavelandy SS; Fox T; Mazza G; Argemi J; Bataller R; Cowart LA; Kester M; Pinzani M; Rombouts K
Cells; 2020 May; 9(5):. PubMed ID: 32429478
[TBL] [Abstract][Full Text] [Related]
4. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
5. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
6. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Musso G; Saba F; Cassader M; Gambino R
Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
[TBL] [Abstract][Full Text] [Related]
7. Concise review of lipidomics in nonalcoholic fatty liver disease.
Béland-Bonenfant S; Rouland A; Petit JM; Vergès B
Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
[TBL] [Abstract][Full Text] [Related]
9. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
[TBL] [Abstract][Full Text] [Related]
10. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
12. Lipidomic signatures discriminate subtle hepatic changes in the progression of porcine nonalcoholic steatohepatitis.
Herrera-Marcos LV; Martínez-Beamonte R; Arnal C; Barranquero C; Puente-Lanzarote JJ; Lou-Bonafonte JM; Gonzalo-Romeo G; Mocciaro G; Jenkins B; Surra JC; Rodríguez-Yoldi MJ; Alastrué-Vera V; Letosa J; García-Gil A; Güemes A; Koulman A; Osada J
Am J Physiol Gastrointest Liver Physiol; 2024 Apr; 326(4):G411-G425. PubMed ID: 38375587
[TBL] [Abstract][Full Text] [Related]
13. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
[TBL] [Abstract][Full Text] [Related]
14. DEAD-Box Helicase 17 exacerbates non-alcoholic steatohepatitis via transcriptional repression of cyp2c29, inducing hepatic lipid metabolism disorder and eliciting the activation of M1 macrophages.
Ning D; Jin J; Fang Y; Du P; Yuan C; Chen J; Huang Q; Cheng K; Mo J; Xu L; Guo H; Yang MJ; Chen X; Liang H; Zhang B; Zhang W
Clin Transl Med; 2024 Feb; 14(2):e1529. PubMed ID: 38303609
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.
Peng KY; Watt MJ; Rensen S; Greve JW; Huynh K; Jayawardana KS; Meikle PJ; Meex RCR
J Lipid Res; 2018 Oct; 59(10):1977-1986. PubMed ID: 30042157
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis.
Li H; Xu QY; Xie Y; Luo JJ; Cao HX; Pan Q
Ann Hepatol; 2021; 24():100316. PubMed ID: 33515803
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease.
Mato JM; Alonso C; Noureddin M; Lu SC
World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337
[TBL] [Abstract][Full Text] [Related]
18. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats.
Deng Y; Pan M; Nie H; Zheng C; Tang K; Zhang Y; Yang Q
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683679
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of scutellaria-coptis herb couple against non-alcoholic steatohepatitis via activating NRF2 and FXR pathways in vivo and in vitro.
Xue Y; Wei Y; Cao L; Shi M; Sheng J; Xiao Q; Cheng Z; Luo T; Jiao Q; Wu A; Chen C; Zhong L; Zhang C
J Ethnopharmacol; 2024 Jan; 318(Pt A):116933. PubMed ID: 37482263
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease.
Deng KQ; Huang X; Lei F; Zhang XJ; Zhang P; She ZG; Cai J; Ji YX; Li H
Am J Physiol Cell Physiol; 2022 Aug; 323(2):C630-C639. PubMed ID: 35759443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
